摘要
目的探讨艾迪注射液辅助经肝动脉化疗灌注栓塞术(TACE)治疗晚期原发性肝癌的临床疗效。方法将116例原发性肝癌患者随机分成2组,各58例。对照组采用经肝动脉灌注栓塞术治疗。观察组在经肝动脉灌注栓塞术治疗基础上加用艾迪注射液辅助治疗。结果观察组总有效率为87.93%,高于对照组总有效率70.69%,差异具有统计学意义(P<0.05)。治疗后,观察组患者躯体功能、角色功能、情绪功能、社会功能、整体生活质量、疲乏、疼痛、恶心呕吐、失眠、食欲丧失、腹泻等评分均优于对照组,差异具有统计学意义(P<0.01)。治疗后,观察组患者血清AFP(60.9±16.9)μg/L、ICAM-1(274.9±73.5)μg/L、VEGF(23.1±8.75)ng/L,都低于对照组患者血清AFP(80.1±18.2)μg/L、ICAM-1(396.4±80.5)μg/L、VEGF(32.0±8.3)ng/L,差异具有统计学意义(P<0.01)。结论艾迪注射液辅助经肝动脉化疗灌注栓塞术治疗晚期原发性肝癌,能有效提高疗效,改善患者生活质量,增加患者免疫功能。
Objective To investigate the effect of intervention of Addie injection on serum inflammatory factors and immune function of liver cancer patients after TACE treatment. Methods 116 cases of primary liver cancer patients were randomly divided into 2 groups,58 cases in each. The control group was treated by transcatheter arterial chemoembolization therapy( TACE). The observation group received Addie injection after TACE. Results Total effective rate in the observation group was87. 93%,which was higher than that of the control group 70. 69%,there had significant difference( P < 0. 05). After treatment,physical function,role function,emotional function,social function,the overall quality of life,fatigue,pain,nausea and vomiting,insomnia,loss of appetite,diarrhea score in the observation group were better than those of the control group,there had statistically significant differences( P < 0. 01). After treatment,the serum levels of AFP( 60. 9 ± 16. 9) g / L,ICAM-1( 274. 9 ± 73. 5) g / L,VEGF( 23. 1 ± 8. 75) ng / L in the observation group were lower than those of the control group,the serum levels of AFP( 80. 1 ±18. 2) g / L,ICAM-1( 396. 4 ± 80. 5) g / L,VEGF( 32. 0 ± 8. 3) ng / L,there had statistically significant differences( P < 0. 01).Conclusion Addie injection in adjuvant chemotherapy and TACE for advanced primary liver cancer can effectively improve the curative effects,quality of life,and immune function.
出处
《实用癌症杂志》
2015年第5期658-661,共4页
The Practical Journal of Cancer
关键词
艾迪注射液
肝动脉灌注
原发性肝癌
炎性因子
免疫功能
Addie injection
Transcatheter arterial chemoembolization therapy(TACE)
Primary liver cancer
Inflammatory cytokines
Immune function